3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Leukemia
1
Interventions
Imatinib Mesylate
5
Cyclophosphamide
4
fludarabine
3
Vincristine
3
Methotrexate
3
Dexamethasone
3
Dasatinib
3
Cytarabine
3
fludarabine phosphate
2
Prednisone
2
Daunorubicin
2
venetoclax
1
thymoglobulin
1
ponatinib
1
peginterferon alfa-2a
1
olverembatinib
1
flumatinib
1
blinatumomab
1
Whole-Body Irradiation
1
Tacrolimus
1
Rituximab
1
Prednisolone
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Mycophenolic Acid
1
Mitoxantrone
1
Mercaptopurine
1
Melphalan
1
Magnetic Resonance Imaging
1
Interferons
1
Inotuzumab Ozogamicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Philadelphia Chromosome
×
olverembatinib
×
Lymphoid
×
Clear all
NCT06220487
2024-01-24
ABC
Nanfang Hospital, Southern Medical University
Phase 2
Recruiting
67 enrolled